MDACC Study No:2008-0484 ( NCT No: NCT00787527)
Title:A Phase I/II of Vorinostat plus CHOP in untreated T-cell non-Hodgkin's Lymphoma
Principal Investigator:Yasuhiro Oki
Treatment Agent:Cyclophosphamide; Doxorubicin; Prednisone; Vincristine; Vorinostat
Study Status:Terminated
Study Description:The goal of this clinical research study is to find out how well the drug
Zolinza (vorinostat) works in combination with the drug combination called CHOP
(cyclophosphamide, doxorubicin, vincristine, and prednisone) to treat patients
with untreated T-cell NHL. The safety of these drugs in combination and the
best dose of vorinostat when given in combination with CHOP will also be
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I/Phase II
Treatment Agents:Cyclophosphamide
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Pts will receive CHOP on day 1 of every cycle; Cycles will be repeated every 21
Up to two capsules of vorinostat are to be administered orally twice daily(in
am and pm) in repeated 21-day cycles consisting of 10 days dosing starting on
days 5-14
Supported By:Merck
Return Visit:Days 5 through 14 of each cycle.
Home Care:NA

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yasuhiro Oki
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults